Forus, a US healthcare startup, announced on September 8 that it had closed a 150 million USD (about 23 billion yen) Series C at a 3 billion USD (about 460 billion yen) valuation. The company assigns a dedicated AI agent to each prescription, which handles insurance pre-approval and patient cost-support paperwork on its own. The valuation tripled from its Series B just a few months earlier.
※1 USD = 154 JPY (as of September 9, 2026)
An Insider Round Backed Entirely by Existing Investors
The round was led by Bain Capital Ventures, which has backed Forus since seed. No new investors were added. Every existing institutional backer reinvested, including Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Avra, Human Capital, Neo, Vast Ventures and SV Angel.
Cumulative equity financing now exceeds 300 million USD (about 46 billion yen). Tripling a valuation within months of the Series B, without bringing in an outside party to set the price, is a fairly strong signal from the investors who watch the numbers most closely.
One in Three Patients Never Receives the First Dose
Forus targets a specific breakdown in specialty medicine. According to the company, one in three patients prescribed therapies for high-cost or complex conditions never receives an initial dose. Those who do receive it often wait weeks or months.
The cause is prior authorization, the pre-approval process widely used by US commercial insurers, combined with the financial clearance needed to settle what the patient actually pays. Once a physician decides on a drug, the work that follows piles up: filing with the insurer, appealing a denial, enrolling the patient in assistance programs, and arranging a specialty pharmacy. Treatment stalls there. What keeps patients waiting is not the prescribing decision but everything queued behind it.
One Agent per Prescription, Running Inside the EHR
Forus was founded in 2023 by Sahir Jaggi and positions itself as a network linking prescribing physicians, retail and specialty pharmacies, commercial payers and biopharma commercial teams. The platform is free for both providers and patients, and every qualifying prescription is assigned its own autonomous AI agent. Because the agent runs inside the clinical electronic workflow, physicians and administrative staff do not have to open a separate system.
Each agent behaves much like a dedicated case manager. It reasons across the patient's medical records, the coverage rules of their insurance plan and the assistance programs available, then assembles the path the drug takes to reach the patient. Forus points to 3 effects.
The first is faster prior authorization. By mechanically cross-referencing clinical indications against payer policies that shift from insurer to insurer, approvals that took several weeks are cut to under 48 hours. The second is automated financial assistance, connecting eligible patients in real time to manufacturer copay cards, foundation grants and zero-dollar access programs. The third is specialty pharmacy orchestration: routing prescriptions straight to network-approved dispensing pharmacies with verified stock shortens the start of a complex therapy from months to 1 or 2 weeks.
More Than a Third of Rheumatology Providers, and 9 of the Top 15 Biopharma Firms
The footprint comes with numbers. Providers in all 50 US states use Forus, covering patients in 85 percent of US residential ZIP codes.
In rheumatology, the first specialty the company rolled out to, more than a third of eligible US providers have adopted the network. Follow-on specialties have reached double-digit adoption rates. Starting in an area where prior authorization and financial assistance weigh most heavily, such as biologics for autoimmune disease, was a deliberate choice.
The data the network collects has created a second source of value. It shows where prescriptions stall and how therapies actually perform in real-world settings. Forus now works with 9 of the top 15 global biopharma companies to improve commercial product launches and refine clinical trial protocol design. A tool that began by relieving administrative load on physicians has also started to function as a real-world data layer for drugmakers.
Jaggi says the goal is to put the platform in every doctor's office in the country, so that the best medicine science can offer actually reaches the people who need it.
Summary
The Forus Series C is a case of capital flowing not to a new drug but to the paperwork standing between a drug and a patient. Cutting prior authorization to under 48 hours and matching patients to assistance programs on the spot are unglamorous features, but against a backdrop where one in three patients never receives a first dose, the effect is large. As a use for AI agents, Forus picked a quiet and reliable direction: clearing the administrative work that never finishes inside an existing workflow.
